Cargando…
Anakinra for the treatment of COVID-19 patients: a systematic review and meta-analysis
BACKGROUND: At the end of 2021, the European Medicines Agency (EMA) expanded its approval for the recombinant human interleukin-1 (IL-1) receptor antagonist Anakinra for the treatment of COVID-19 patients with elevated soluble urokinase plasminogen activator receptor (suPAR). However, the role of An...
Autores principales: | Dahms, Karolina, Mikolajewska, Agata, Ansems, Kelly, Metzendorf, Maria-Inti, Benstoem, Carina, Stegemann, Miriam |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9959952/ https://www.ncbi.nlm.nih.gov/pubmed/36841793 http://dx.doi.org/10.1186/s40001-023-01072-z |
Ejemplares similares
-
Safety and Efficacy of Intermediate- and Therapeutic-Dose Anticoagulation for Hospitalised Patients with COVID-19: A Systematic Review and Meta-Analysis
por: Reis, Stefanie, et al.
Publicado: (2021) -
Effects of hypercapnia versus normocapnia during general anesthesia on outcomes: a systematic review and meta-analysis
por: Petran, Jan, et al.
Publicado: (2021) -
Evidence on the efficacy of ivermectin for COVID-19: another story of apples and oranges
por: Popp, Maria, et al.
Publicado: (2022) -
Ivermectin for preventing and treating COVID‐19
por: Popp, Maria, et al.
Publicado: (2021) -
Anticoagulation in COVID-19 patients – An updated systematic review and meta-analysis
por: Reis, Stefanie, et al.
Publicado: (2022)